111 drug samples tested in November found 'not of standard quality': CDSCO

Identification of drug samples as NSQ is done based on failure of the drug sample in one or the other specified quality parameters

medicine, Drugs
Identification of drug samples as NSQ is done based on failure of the drug sample in one or the other specified quality parameters |(Photo: Shutterstock)
Press Trust of India New Delhi
1 min read Last Updated : Dec 28 2024 | 12:30 PM IST

Central Drugs Standard Control Organisation (CDSCO) has found 41 drug samples tested in the central drug laboratories in November as 'not of standard quality' (NSQ), official sources said.

Besides, 70 drug samples tested by the state drugs testing laboratories have also been identified as NSQ in November, they said.

Identification of drug samples as NSQ is done based on failure of the drug sample in one or the other specified quality parameters.

"The failure is specific to the drug products of the batch tested by the government laboratory and it does not warrant any concerns on the other drug products available in the market," an official said.

Two drug samples were identified as spurious drugs in November. Out of the two samples, one was picked by Bihar Drugs Control Authority and the other by CDSCO, Ghaziabad, the sources said.

The drugs were made by unauthorised and unknown manufacturers, using brand names of other companies.

Action to identify NSQ and spurious medicines is taken regularly in collaboration with the state regulators to ensure such drugs are identified and removed from the market, the sources said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Drug safetyIndian drug makersdrug manufacturersCDSCO

First Published: Dec 28 2024 | 12:30 PM IST

Next Story